Sugi Predict

Sugi Predict / Targets / CCNK

CCNK

Cyclin-K · O75909 · CCNK on Sugi Atlas →

62,637 patent compounds predicted against CCNK, 38,388 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL268925 SCHEMBL268925 0.50 18/20
SCHEMBL269583 SCHEMBL269583 0.50 18/20
SCHEMBL517413 SCHEMBL517413 0.54 12/20
SCHEMBL517461 SCHEMBL517461 0.54 11/20
SCHEMBL559356 SCHEMBL559356 0.51 11/20
SCHEMBL1089473 SCHEMBL1089473 0.50 11/20
SCHEMBL1089125 SCHEMBL1089125 0.55 9/20
SCHEMBL889079 SCHEMBL889079 0.49 9/20
SCHEMBL936028 SCHEMBL936028 0.46 9/20
SCHEMBL517664 SCHEMBL517664 0.48 8/20
SCHEMBL610952 SCHEMBL610952 0.48 8/20
SCHEMBL99955 SCHEMBL99955 0.56 7/20
SCHEMBL1089142 SCHEMBL1089142 0.54 7/20
SCHEMBL1089153 SCHEMBL1089153 0.54 7/20
SCHEMBL102731 SCHEMBL102731 0.53 7/20
SCHEMBL1088930 SCHEMBL1088930 0.53 7/20
SCHEMBL559412 SCHEMBL559412 0.50 7/20
SCHEMBL559413 SCHEMBL559413 0.50 7/20
SCHEMBL99686 SCHEMBL99686 0.47 7/20
SCHEMBL559189 SCHEMBL559189 0.47 7/20

Clinical trials — most relevant to CCNK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study PHASE3RECRUITING
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Sirolimus in Treating Patients With Advanced Pancreatic Cancer PHASE2COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. PHASE2COMPLETED
Palbociclib and Pembrolizumab In Central Nervous System Metastases PHASE2RECRUITING
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors PHASE2WITHDRAWN
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors PHASE1/PHASE2COMPLETED
Study of AVZO-021 in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA PHASE1RECRUITING
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets PHASE1UNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study nanACTIVE_NOT_RECRUITING
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CCNK binder may also engage these)

ProteinNameSimilarity
O88874 — 1.000 O88874 →
F1QMB9 — 0.981 F1QMB9 →
Q4VGL6 — 0.975 Q4VGL6 →
Q6NUC6 — 0.972 Q6NUC6 →
Q5TC82 — 0.966 Q5TC82 →
Q9H0L4 — 0.963 Q9H0L4 →
MED25 Mediator of RNA polymerase II transcription subunit 25 0.963 landscape →
Q6NZ18 — 0.963 Q6NZ18 →
Q8C7E9 — 0.961 Q8C7E9 →
Q8BIQ5 — 0.961 Q8BIQ5 →
P48377 — 0.960 P48377 →
P0C090 — 0.960 P0C090 →
Q8VCB2 — 0.960 Q8VCB2 →
Q80XC3 — 0.960 Q80XC3 →
Q8K4S7 — 0.959 Q8K4S7 →
Q9HBD1 — 0.959 Q9HBD1 →
Q9UQB3 — 0.959 Q9UQB3 →
Q3TTA7 — 0.959 Q3TTA7 →
Q6PEH8 — 0.958 Q6PEH8 →
Q80TJ7 — 0.958 Q80TJ7 →
Q6NRE7 — 0.958 Q6NRE7 →
P33240 — 0.958 P33240 →
Q8HXM1 — 0.957 Q8HXM1 →
Q64213 — 0.957 Q64213 →
A2VE44 — 0.957 A2VE44 →
P18514 — 0.957 P18514 →
P51126 — 0.957 P51126 →
Q6DEZ2 — 0.957 Q6DEZ2 →
Q9Z1X4 — 0.957 Q9Z1X4 →
Q6DD04 — 0.957 Q6DD04 →